Table 2. Description of data extracted from the included studies in the meta-analysis searching for an association between toxoplasmosis and epilepsy.
| Reference | N | Age | EP+ (n) | EA- (n) | EP & T+(n, %) | EA & T+ (n, %) | OR (95% CI) | P-value |
|---|---|---|---|---|---|---|---|---|
| Potasman (1987–91, Israel) | 161 | 1–15 | 52 | 109 | 10 (19.2%) | 10 (9.0%) | 2.36 (0.91–6.08) | 0.11 |
| Stommel (1997–99, USA) | 45 | adults | 22 | 23 | 17 (75.0%) | 13 (56.5%) | 2.62 (0.72–9.54) | 0.075 |
| Yazar (1999–2002, Turkey) | 100 | adults | 50 | 50 | 27 (54.0%) | 9 (25.0%) | 5.35 (2.15–13.30) | <0.001 |
| Akyol (2003, Turkey) | 150 | 11–64 | 100 | 50 | 31 (31.0%) | 10 (20.0%) | 1.80 (0.80–4.05) | 0.2 |
| Zibaei (2010, Iran) | 170 | 7–62 | 85 | 85 | 12 (14.1%) | 4 (4.7%) | 3.33 (1.03–10.78) | 0.036 |
| Ngugi (2007–11, SSA) | 2262 | All | 971 | 1291 | 380 (39.1%) | 457 (35.4%) | 1.17 (0.99–1.39) | 0.06 |
Age is in years; CI: Confidence interval; EP+: People with epilepsy; EA-: People without epilepsy; EP & T+: People with epilepsy and Toxoplasma positive; EA & T+: People without epilepsy and Toxoplasma positive; OR: Odds ratio; SSA: Sub-saharan Africa